Royce & Associates LP Reduces Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Royce & Associates LP lowered its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 9.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 825,133 shares of the medical equipment provider's stock after selling 87,519 shares during the period. Royce & Associates LP owned approximately 1.79% of BioLife Solutions worth $20,661,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in BioLife Solutions by 249.5% during the 1st quarter. BNP Paribas Financial Markets now owns 53,515 shares of the medical equipment provider's stock valued at $993,000 after acquiring an additional 38,201 shares during the period. Texas Permanent School Fund Corp raised its stake in shares of BioLife Solutions by 4.7% during the 1st quarter. Texas Permanent School Fund Corp now owns 31,145 shares of the medical equipment provider's stock valued at $578,000 after purchasing an additional 1,384 shares during the period. Swiss National Bank lifted its holdings in BioLife Solutions by 3.6% during the 1st quarter. Swiss National Bank now owns 71,100 shares of the medical equipment provider's stock worth $1,319,000 after purchasing an additional 2,500 shares in the last quarter. Sei Investments Co. boosted its stake in BioLife Solutions by 1.4% in the 1st quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider's stock worth $1,117,000 after purchasing an additional 839 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in BioLife Solutions by 6.1% during the 1st quarter. Russell Investments Group Ltd. now owns 194,126 shares of the medical equipment provider's stock valued at $3,601,000 after buying an additional 11,076 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS traded down $0.63 during trading on Friday, reaching $21.02. The company had a trading volume of 900,487 shares, compared to its average volume of 379,789. The company has a fifty day moving average of $24.00 and a two-hundred day moving average of $22.78. The company has a current ratio of 2.78, a quick ratio of 1.81 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $975.12 million, a P/E ratio of -19.83 and a beta of 1.88. BioLife Solutions, Inc. has a 12 month low of $11.40 and a 12 month high of $28.88.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. TD Cowen increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday. HC Wainwright assumed coverage on shares of BioLife Solutions in a research note on Monday, September 30th. They issued a "buy" rating and a $29.00 target price on the stock. Craig Hallum boosted their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Northland Securities increased their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $27.83.

Insider Activity at BioLife Solutions

In related news, CRO Garrie Richardson sold 3,070 shares of the business's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. The trade was a 2.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,593,412.40. The trade was a 3.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,471 shares of company stock valued at $656,330 over the last 90 days. 2.20% of the stock is owned by insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.